In an exclusive interview with Lifestyle Forum, Chairman Tse-Wen Chang highlighted the innovative drug design of TE-8214 and its potential breakthrough applications in clinical settings.
Looking ahead to 2026, Immunwork will initiate the next phases of clinical trials for both TE-8214 and TE-8105, continuing to evaluate their therapeutic potential while further optimizing dosing strategies and clinical applications.
The interview video:
https://youtu.be/fnxQxlp84J4
Related News:
https://www.ctwant.com/article/463164/
https://www.styletc.com/article/463152/